A client is prescribed epoetin alfa. The nurse understands that this medication is most commonly used to treat anemia associated with which condition?

Introduction: Epoetin alfa is a recombinant form of the endogenous glycoprotein erythropoietin, which is primarily synthesized by the peritubular cells of the kidney. It stimulates erythropoiesis by binding to receptors on committed erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation into mature erythrocytes. A. In CHRONIC KIDNEY DISEASE (CKD), the renal parenchyma is unable to produce sufficient quantities of natural erythropoietin. This deficiency is the primary driver of RENAL ANEMIA. Epoetin alfa is the standard of care to maintain hemoglobin levels and reduce the necessity of blood transfusions in these patients. B. Vitamin B12 deficiency causes megaloblastic anemia due to impaired DNA synthesis. The treatment for this condition is the administration of cyanocobalamin, not epoetin alfa. Administering an erythropoiesis-stimulating agent without addressing the underlying nutritional deficiency would be ineffective, as the marrow lacks the building blocks for healthy cell production. C. Advanced osteoporosis with fractures involves skeletal mineralization defects and mechanical bone failure. While significant blood loss from a major fracture could theoretically lead to anemia, epoetin alfa is not a standard or indicated treatment for osteoporosis-related issues. Management focuses on bisphosphonates, calcium, vitamin D, and surgical stabilization. D. Iron deficiency anemia is characterized by microcytic, hypochromic red blood cells and is treated with oral or parenteral iron supplementation. While iron is necessary for epoetin alfa to work effectively, epoetin alfa itself is not indicated as a primary treatment for dietary iron deficiency in the absence of chronic renal failure.